



This site uses cookies. By continuing to browse this Business Wire site (and/or any other Business Wire website), you accept the use of cookies. [Learn more \(/portal/site/home/privacy/\)](/portal/site/home/privacy/)



[I agree](#)

Noxopharm Investigating Potential COVID-19 Treatment

April 02, 2020 08:00 AM Eastern Daylight Time

SYDNEY--(BUSINESS WIRE)--Noxopharm, a clinical-stage Australian oncology drug development company, has identified a clinical trial opportunity that could help reduce the mortality rate of COVID-19.

Noxopharm has a primary focus on the development of Veyonda®, with the active ingredient, idronoxil. [Hudson Institute of Medical Research in Melbourne](#) has found in preclinical research that idronoxil inhibits a range of inflammatory mediators known as cytokines, including interleukin-6 (IL-6), that are involved in a process known as a cytokine response syndrome (or cytokine storm). Cytokine storm is associated with an excessive and abnormal inflammatory response and is believed to be responsible for most deaths in patients with COVID-19 infection.

Noxopharm will pursue a potential clinical study to evaluate the use of idronoxil in patients considered to be at risk of developing COVID-19 associated acute respiratory distress syndrome (ARDS) and multi-organ failure.

“Our research indicates that idronoxil is a potent inhibitor of IL-6 production in the context of tissue damage seen in ARDS,” said [Dr. Michael Gantier](#), Head of the Nucleic Acids and Innate Immunity Laboratory at Hudson Institute. “However, unlike strategies targeting IL-6 itself, our findings suggest that idronoxil blocks the process of IL-6 production along with that of other key mediators of organ failure.”

“Noxopharm is focused on developing Veyonda® as a treatment for late-stage prostate cancer,” said [Dr. Graham Kelly](#), Noxopharm CEO. “However, when you are told by respected scientists that your lead drug candidate is working in a way that might prevent thousands of deaths in a global pandemic, you don’t walk away from that possibility. Having idronoxil already in the clinic means that we are in a position to commence clinical testing.”

About Noxopharm

[Noxopharm](#) is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in the non-oncology drug development company, Nyrada Inc.

Contacts

Jane Byram

SCORR Marketing

512-626-2758

jane@scorrmktg.com

Tweets by @noxopharm

**Noxopharm Ltd**

@noxopharm

This site uses cookies. By continuing to browse this Business Wire site (and/or any other Business Wire website), you accept the use of cookies. [Learn more \(/portal/site/home/privacy/\)](#)

I agree

Apr 1, 2020

**Noxopharm Ltd**

@noxopharm

Veyonda Awarded First Allowed Patent Application

noxopharm.com/site/PDF/93f40...


Mar 23, 2020

Noxopharm Ltd Retweeted

**National Cancer Institute**

@theNCI

What's the abscopal effect? It's a rare and remarkable response to treatment for cancer, as this summary explains: cancer.gov/news-events/ca... #abscopal #abscopaleffect #CancerResearch



#Hashtags

[#clinicaltrials](#)[#covid19](#)[#prostatecancer](#)

Social Media Profiles

[Noxopharm on LinkedIn](#)